Skip to content
Nanopharm-logo-with-signature-Pantone (1)
  • Home
  • About Us

    About Us

    Leadership Team

    Our Scientists
  • Services

    Product Development

    Preformulation & Preclinical

    Formulation & Drug Product Development

    Clinical Development

    Clinical Trial Manufacturing

    cGMP Release & Stability Testing

    Analytical Services

    Research & Development

    Spray Characterization

    Method Development
    cGMP Release & Stability

    IVBE & CMC Studies

    Alternative Bioequivalence

    In-Silico Modeling

    SmartTrack™

    PBPK Modeling

    Regional Deposition Modeling

    Regulatory

    Consultancy

    Alternative Bioequivalence
  • OINDP Expertise

    Nasal

    Nasal Powders

    Nasal Sprays

    Nasal Cast Deposition

    Inhalation

    DPI

    pMDI

    Low GWP Propellant pMDI

    Nebulizers

    Inhaled Biologics

    Generics & Lifecycle Management

    Reformulation & Repositioning

    IVBE

    Alternative Bioequivalence
  • Resources

    Resources

    Scientific Publications

    White Papers

    Posters
  • News & Events
  • Contact Us
  • Careers

Mixed Kinetic Model of Inhaled Corticosteroid Dissolution

Explore the dissolution kinetics of inhaled pharmaceuticals in dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI).

Automated Classification of DPI Agglomerate Particles

Explore automated classification of dry powder inhaler particles using Cluster Analysis and Morphologically Directed Raman Spectroscopy.

Alternative regulatory path for generic Respiratory Products

Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.

Challenges in OINDPs Achieving Q3 Equivalence

Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.

Trade Marks Registration Certificate for Nanopharm Ltd

Discover Nanopharm’s leading role in pharmaceutical research, specializing in OINDP, nasal, and inhaled pharmaceutical solutions.

Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence

Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.

Characterizing Nasal Suspensions for Regulatory and Scientific Purposes

Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.

Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers

Explore Nanopharm’s in-depth in vitro study on dry powder inhalers (DPIs). Learn how Computational Fluid Dynamics and Particle Size Distribution contribute to device performance and comparability.

The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate

Nanopharm explores structural dynamics of Fluticasone Propionate in DPIs. Focus on APSD in Dry Powder Inhaler formulations.

Structural Dynamics of Fluticasone Propionate Processing

Nanopharm explores the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate.

← Previous
Next →
  CONTACT
+44 (0) 1633 372200
info@nanopharm.co.uk

Nanopharm Ltd
Franklin House, Grange Road, Cwmbran, NP44 3WY, United Kingdom   

STAY CONNECTED

Linkedin Youtube
General Terms and Conditions of Use and Privacy Policy
Terms & Conditions of Sales

© 2024. Nanopharm Ltd. All rights reserved.